Next Article in Journal
2019 FDA TIDES (Peptides and Oligonucleotides) Harvest
Previous Article in Journal
[68Ga]Ga-DOTA-TOC: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging
Previous Article in Special Issue
Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology
Open AccessReview

(Radio)Theranostic Patient Management in Oncology Exemplified by Neuroendocrine Neoplasms, Prostate Cancer, and Breast Cancer

Science for Life Laboratory, Department of Medicinal Chemistry, Uppsala University, 751 83 Uppsala, Sweden
Pharmaceuticals 2020, 13(3), 39; https://doi.org/10.3390/ph13030039 (registering DOI)
Received: 19 January 2020 / Revised: 1 March 2020 / Accepted: 3 March 2020 / Published: 5 March 2020
The role of nuclear medicine in the management of oncological patients has expanded during last two decades. The number of radiopharmaceuticals contributing to the realization of theranostics/radiotheranostics in the context of personalized medicine is increasing. This review is focused on the examples of targeted (radio)pharmaceuticals for the imaging and therapy of neuroendocrine neoplasms (NENs), prostate cancer, and breast cancer. These examples strongly demonstrate the tendency of nuclear medicine development towards personalized medicine. View Full-Text
Keywords: (radio)theranostics; somatostatin; neuroendocrine neoplasms; prostate cancer; breast cancer; PSMA; PET; SPECT; gallium-68; lutetium-177 (radio)theranostics; somatostatin; neuroendocrine neoplasms; prostate cancer; breast cancer; PSMA; PET; SPECT; gallium-68; lutetium-177
Show Figures

Figure 1

MDPI and ACS Style

Velikyan, I. (Radio)Theranostic Patient Management in Oncology Exemplified by Neuroendocrine Neoplasms, Prostate Cancer, and Breast Cancer. Pharmaceuticals 2020, 13, 39.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop